Overview

A Safety Study of SGN-CD19A for B-Cell Lymphoma

Status:
Completed

Trial end date:
2017-02-16

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)

Phase:

Phase 1

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Antibodies